Breadcrumb

[A17-22] Reslizumab (asthma) - Addendum to Commission A17-02

Overview

Overview

Commission: Commission awarded on 2017-05-22 by the Federal Joint Committee (G-BA)
Status:Commission completed
Department/Division:Drug Assessment
Current document:PDF Addendum to Commission A17-02  [PDF, 169 kB] (German version) Further documents
Note:

If the need for additional work on a project commissioned by the G-BA arises during consultations, then IQWiG presents a report in the form of an "addendum". The G-BA subsequently decides on the extent of the added benefit, thus completing the early benefit assessment.

Contact address:to the contact form
Linked projects: [A17-02] Reslizumab (severe eosinophilic asthma) – Benefit assessment according to § 35a Social Code Book V
Status: Commission completed


Report documents

Report documents

PublishedDocumentSizeType 
2017-07-06 Addendum to Commission A17-02 (German version) 169 kBPDFdownload file

If the need for additional work on a project commissioned by the G-BA arises during consultations, then IQWiG presents a report in the form of an "addendum". The G-BA subsequently decides on the extent of the added benefit, thus completing the early benefit assessment.


At a glance

Accompanying information

Federal Joint Committee (G-BA)

2017-07-06 A G-BA decision was published.

G-BA documents on this decision



Save result list

To save your search result, please copy the link below and paste it into a new tab/window.

close